

This workplan is updated monthly and includes topics in active development. Find the most recent version [on our website](#)

- To suggest a topic or enquire about anything on this workplan, please email us at nuth.nyrdtc.rxsupp@nhs.net.
- To view a list of recently published items, visit the [recent publications](#) page of our website.
- See the end of the workplan for descriptions of each type of publication, and anticipated publication frequency.

Regular publications

A wide range of regular publications are produced on a frequent basis, as outlined below. They are available to staff at NHS stakeholder organisations via the [RDTC website](#) (login required).

Title	Publication anticipated (financial quarter)
Monthly financial headlines Monitor budget performance based on total prescribing at sub-ICB and PCN level for the financial year to date	Monthly, approx. 7 working days after ePACT2 data published
Monthly formulary amendments Summary of issues impacting local formularies, including NICE guidance, RMOC outputs, Drug Safety Updates, and NPSA alerts	Monthly, before the 10 th of the month
Monthly horizon scanning report Summary of new products and licenses, significant new guidance, and decisions from recognised national and regional bodies	Monthly, before the 16 th of the month
Therapeutic reports Examine prescribing trends in a specific therapeutic area, at ICB and SICBL levels. Prescribing data is weighted with QoF registers, and uses HES data where possible to measure prescribing and outcomes.	Quarterly or six-monthly. Next publication date:
Antimicrobial drugs , data period Q2 2022/23	Q4 (Jan-Mar)
Cardiovascular system , data period Q2 2022/23	Q4 (Jan-Mar)
Drugs used in diabetes , data period Q2 2022/23	Q4 (Jan-Mar)
Drugs for dementia , data period Q2 2022/23	Q4 (Jan-Mar)
Respiratory , data period Q2 2022/23	Q4 (Jan-Mar)
Pain management , data period Q2 2022/23	Q4 (Jan-Mar)

Title	Publication anticipated (financial quarter)
RDTC newsletter Update on RDTC activities, to help tailor local work plans and highlight topical issues in prescribing or medicines management.	Every two months Next edition: March 2023
Cost comparison charts Cost charts, organised by BNF classification, showing comparative costs at the NHS basic price.	Quarterly Next edition: Q4 (Jan-Mar)
Price concession bulletin Predicted cost impact of drug price changes, both through the Price Concessions list and monthly Drug Tariff cost variations	Monthly Next edition: Q4 (Jan-Mar)
Top 50 BNF sections and drugs Top 50 BNF sections and drugs in terms of spend at SICBL level for the financial year to date, with a focus on growth	Quarterly Next edition: Q4 (Jan-Mar)
Growth contrast tool Identify important local effects on prescribing costs by comparing growth with national patterns	Quarterly Next edition: Q4 (Jan-Mar)
Drug tariff monitor Predicted cost impact of Drug Tariff category A, M and C price changes on primary care spending	Quarterly Next edition: Q4 (Jan-Mar)

Forthcoming publications

To feedback on new or updated publications or take part as an external commentator, please email us at nuth.nyrdtc.rxsupp@nhs.net. Regular publications are produced on a regular schedule, as outline below. They are available to all staff at NHS stakeholder organisations via the [RDTC website](#) (login required).

Title	Type	Topic	Publication anticipated (financial quarter)
Polypharmacy: prescribing cascades	Prescribing for population health	Medicines safety	Q4 (Jan-Mar)
Linzagolix for uterine fibroids	New drug evaluation	Diabetes and endocrine	Q4 (Jan-Mar)
Actimorph (oral morphine)	Formulary assessment tool	CNS	Q4 (Jan-Mar)
Opioid population demographics	Prescribing for population health	Medicines safety	Q4 (Jan-Mar)
Opioid population health management	Prescribing for population health	Medicines safety	Q4 (Jan-Mar)

Title	Type	Topic	Publication anticipated (financial quarter)
Inhaler carbon impact assessment tool (update)	Prescribing data report	Respiratory	Q4 (Jan-Mar)
Disposal of inhalers	Prescribing bulletin	Medicines value	Q4 (Jan-Mar)
Incorporating primary and secondary care prescribing data to better understand the ICS	Prescribing for population health	Medicines value	Q4 (Jan-Mar)
Patient concordance: evaluation of the accuracy of dispensed medicines data to understand concordance with prescribed dose	Prescribing for population health	Medicines safety	Q4 (Jan-Mar)
Defining the diabetic population drug combinations; a first step to understanding the impact of pathway choices	Strategic insights	Diabetes and endocrine	Q1 (Jan-Mar)
Antimicrobial prescribing	Prescribing for population health	Antimicrobial	Q1 (Apr-Jun)
Reducing inhaler carbon impact	Medicines in Practice	Respiratory	Q1 (Apr-Jun)
Electronic repeat dispensing: implementation, clinical considerations, and thresholds	Strategic insights	Medicines value	Q1 (Apr-Jun)
Polypharmacy: opioids in urgent and emergency care	Strategic insights	Medicines safety	Q1 (Apr-Jun)
Health inequalities and inhaler prescribing	Prescribing for population health	Medicines value	Q1 (Apr-Jun)
Social prescribing: impact on medicines prescribing and other outcomes	Strategic insights	Medicines value	Q1 (Apr-Jun)

Who we are and what we do

We are an NHS organisation hosted by an NHS Foundation Trust. The unit is a multidisciplinary group of senior pharmacists, a medicines evaluation team, and data analysts and statistician. We work closely with many NHS organisations to support collaborative working across systems and sectors.

Below is a list of outputs, with a summary of their content and frequency. If you identify a topic that fits into one or more of these categories and would benefit your team or work streams, please get in touch at nuth.nyrdtc.rxsupp@nhs.net to discuss. See our website for a list of [recent publications](#).

Type	Description	Frequency
Evidence evaluation and medicines optimisation		
Intended audience: medicines optimisation teams, formulary and prescribing committees, and prescribers		
New drug evaluation	Concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.	6-12 annually
Medicines in practice	Evidence-based publications designed to support medicines optimisation activities. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.	
Evaluation reports	Evidence-based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.	
Prescriber support tools	Tools to support medicines management teams and prescribers in clinical decision-making, such as comparison tables for a therapeutic class to highlight clinical similarities and differences.	
Safer medication use	Bulletin series jointly produced with the Yellow Card Centre Northern and Yorkshire, discussing specific drug related safety problems. Provides guidance to ensure safe, appropriate prescribing and raises awareness of adverse drug reaction detection and reporting.	
Formulary assessment tool	Templates to support local decision-making, pre-populated with information required to make a formulary decision on the specific product. Intended to reduce duplication of effort, with space for the addition of local information as appropriate.	10-12 annually
Newsletter	Informs readers of RDTc activities, to help tailor local work plans and highlight topical issues in prescribing or medicines management.	Every two months

Prescribing data reports and analysis		
Intended audience: medicines optimisation teams, medicines commissioning and finance teams		
Monthly financial headlines	Monitors budget performance based on total prescribing for the whole BNF at SICBL and PCN level for the financial year to date with particular focus on cost and item growth compared to the same period from the previous financial year.	Monthly
Therapeutic reports	Therapeutic reports examine prescribing trends in a specific therapeutic area, at SICBL and ICB levels. Prescribing data is weighted with QoF registers, and uses HES data where possible to measure prescribing and outcomes.	Quarterly or six monthly, depending on topic
Cost comparison charts	Over 80 charts, organised by BNF classification, showing comparative costs at the NHS basic price. Charts generally show annual costs at the indicated doses.	Quarterly
Drug tariff monitor	Predicted cost impact of Drug Tariff category A, M and C price changes on primary care spending, calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the Drug Tariff.	Quarterly
Price concession bulletin	Predicted cost impact of drug price changes, both through the Price Concessions list and monthly Drug Tariff cost variations. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the Drug Tariff.	Monthly
Top 50 BNF sections & drugs	Top 50 BNF sections and drugs in terms of spend at SICBL level for the financial year to date, with a focus on cost growth and item growth.	Quarterly
Growth contrast	Identify important local effects on prescribing costs. Figures derived by comparing growth in prescribing costs and items in selected SICBLs with what might have happened if national growth patterns had applied.	Quarterly
Strategic and planning resources		
Intended audience: strategic medicines optimisation and commissioning teams and committees		
Annual horizon scanning	A Key Considerations document and cost calculator, covering medicines and indications expected to launch in the coming 12-15 months. Includes current prescribing budget position, and suggesting proposed uplifts to prescribing budgets for the next financial year.	Annual
Prescribing bulletins	Bulletins covering focused medicines optimisation issues such as the implementation of national guidelines. Estimates potential financial and commissioning impacts and signposts to useful resources.	Quarterly
Inhaler carbon impact assessment tool	Tool intended for use at a commissioning level to estimate the impact of respiratory pathway choices made following a clinical decision-making process.	Six monthly

Prescribing for population health	Bulletins intended to support ICSs to improve the health of the populations they serve, using prescribing data, biomedical literature and other data sources to provide new insights.	Four per year
Financial impact and outcome assessments	Assessment of the financial impact and health outcomes associated with implementing a health technology, clinical pathway or guideline, using a multidisciplinary approach including biomedical evidence, prescribing analysis, and health economics methodology.	Two per year
Professional secretarial services and functions		
Intended user: medicines optimisation groups, e.g. GMMMG , NTAG		
Professional secretarial services	Running of a group, including agenda setting, minute taking, governance (including ToR prep), annual report, decision summaries, newsletters, membership maintenance, and maintaining a DOI register.	As required. Contact the Centre using the details below to discuss options in full.
Enquiry answering	Answering or redirecting enquiries specifically related to the group and its decisions	
Sharing of group decisions	Uploading of decisions to a formulary platform or website (does not include provision of platform or website by RDTC)	
Provision and maintenance of a group website	Provision of a platform or website, and maintenance of content such as group decisions, pathways and guidelines, and meeting minutes.	
Consultation management	The management of a consultation process to include preparing consultation questions, uploading documents, collating responses, and passing to document author(s) for action.	
Formulary maintenance		
Intended audience: local or regional formulary committees		
Formulary maintenance	Assessment of formulary applications, full and regular reviews of formulary, and routine amendments to reflect national guidance and safety alerts.	As required. Contact the Centre using the details below to discuss options in full.
Pathways and guidelines support		
Intended audience: local, regional or national clinical networks and medicines optimisation groups		
Clinical pathway checking or revision	Clinical checking or revision of clinical guidelines, pathways, or shared care protocols, to provide assurance on clinical appropriateness and safety.	As required. Contact the Centre using the details below to discuss options in full.
Clinical pathway development	Development of clinical guidelines, pathways, or shared care protocols, using robust and transparent processes to ensure high quality.	
Working group support	Running a clinical working group, decision group, or task and finish group to support production or revision of clinical guidelines and pathways.	

Basic financial and commissioning impact	Determining the basic impacts of a pathway or guideline, including impact on commissioned services	
Strategic support Intended audience: local or regional strategic medicines groups		
Medicines plan development	Development of an integrated care system medicines plan produced annually and revised bi-annually. Accompanied by a monitoring and assurance schedule.	As required. Contact the Centre using the details below to discuss options in full.
Group attendance	Attendance at a regular committee or group meeting, in an advisory capacity, to provide strategic input.	